Tirzepatide Demonstrates Superior Diabetes Glycemic Control, Weight Loss vs Semaglutide

Tirzepatide, a novel twin glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, confirmed superior and clinically significant enchancment in metrics of glycemic management versus semaglutide in sufferers with type 2 diabetes receiving metformin.

The findings, introduced on the American Diabetes Association (ADA) 2021 Scientific Sessions this week, moreover confirmed the investigative remedy bettered semaglutide—just lately accredited by the US Food and Drug Administration (FDA) for overweight/obese grownup persistent weight administration—in physique weight discount amongst handled sufferers.

The noninferiority SURPASS-2 trial of the Eli Lilly and Company product added to tirzepatide’s portfolio as a possible agent for sort 2 diabetes administration.

Led by Juan Pablo Frias, MD, Medical Director of the National Research Institute, investigators performed the open-label, 40-week part 3 evaluation in search of noninferiority of once-weekly tirzepatide to semaglutide in sufferers with sort 2 diabetes taking background metform.

They had been randomized 1:1:1:1 to tirzepatide 5, 10 or 15 mg dose, or semaglutide 1 mg. Frias and colleagues sought a major efficacy goal of tirzepatide 10 or 15 mg noninferiority versus semaglutide in imply HbA1C change from baseline to week 40.

Secondary endpoints included noninferiority of the lesser-dose tirzepatide (5 mg) for glycemic change per HbA1C, in addition to superiority for all tirzepatide doses for HbA1C change, physique weight and fasting serum glucose enchancment, proportion of sufferers with HbA1C <7%, ≤6.5% and <5.7% at 40 weeks, and physique weight lack of ≥5%, ≥10% and ≥15% at 40 weeks.

The 1879-patient inhabitants included a imply baseline HbA1C of 8.28%. Mean affected person age was 56.6 years previous, with a sort 2 diabetes analysis length of 8.6 years. Mean physique mass index was 34.2 kg/m2.

Investigators noticed superiority of tirzepatide versus semaglutide for imply change in HbA1C, fasting serum glucose, and physique weight with all 3 doses at 40 weeks. Patients handled with tirzepatide additionally reported superiority in HbA1C and physique weight reduction targets at trial’s finish.

Commonly reported hostile occasions in handled sufferers included gastrointestinal results—largely delicate to average in severity. Instances of clinically vital or extreme hypoglycemia occasions had been low amongst handled sufferers.

“In conclusion, all tirzepatide doses demonstrated superior and clinically significant enchancment in glycemic management and substantial weight reduction vs. semaglutide 1 mg in folks with sort 2 diabetes handled with metformin,” investigators wrote.

The research, “Efficacy and Safety of Tirzepatide vs. Semaglutide Once-Weekly as Add-On Therapy to Metformin in People with Type 2 Diabetes (SURPASS-2),” was introduced at ADA 2021.

Recommended For You

About the Author: Adrian

Leave a Reply